Form 4: Neurocrine CSO's Stock Activity: RSU Vesting & Tax Withholding

Neurocrine Biosciences' Chief Scientific Officer, Jude Onyia, reported the routine vesting of restricted stock units and subsequent tax withholding on January 31, 2026.

Summary

• Jude Onyia, Chief Scientific Officer of Neurocrine Biosciences Inc. (NBIX), reported transactions related to common stock and restricted stock units (RSUs).
• On January 31, 2026, 238 shares of common stock were acquired through the vesting of RSUs at an exercise price of $0.
• Concurrently, 142 shares of common stock were disposed of at a price of $136.06 per share to satisfy tax withholding requirements on the RSU vesting.
• No shares were sold by the reporting person; the disposition was solely for tax purposes.
• Following these transactions, Jude Onyia beneficially owns 15,977 shares of Neurocrine Biosciences common stock.
• The RSU award, granted on January 31, 2022, vested in tranches, with the final 238 shares vesting on January 31, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. It reflects the routine execution of executive compensation plans, which is a positive for management retention and alignment, but does not provide new material information about the company's operational or financial performance.

Positives

• The vesting of Restricted Stock Units (RSUs) represents a scheduled compensation event, indicating the execution of long-term incentive plans for the Chief Scientific Officer.
• The disposition of shares was solely for tax withholding purposes, not an open market sale by the officer, which typically does not signal a lack of confidence in the company.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

StockSavvy.ai notes that RSU vesting and subsequent tax withholding are standard practices in executive compensation across the biotechnology and pharmaceutical industries. This type of transaction is a routine part of long-term incentive plans designed to align executive interests with shareholder value over time.

Comparison to Industry Standards

• The mechanism of RSU vesting and tax withholding is a common compensation structure, aligning with practices seen at comparable biotech firms such as Amgen (AMGN) or Gilead Sciences (GILD), where executives receive equity awards that vest over several years.
• The reported transaction price of $136.06 for tax withholding is reflective of the market value of NBIX common stock on the transaction date, consistent with standard accounting and tax procedures for equity compensation across the industry.

Stakeholder Impact

• Shareholders: The transaction is a routine compensation event and does not directly impact the company's operational performance or strategic direction. It reflects the ongoing compensation structure for key executives.
• Employees: This filing highlights the company's use of equity-based compensation, which can be a positive for employee morale and retention, particularly for senior leadership.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction involving the vesting of restricted stock units and subsequent tax withholding. It does not indicate any discretionary buying or selling by the Chief Scientific Officer that would signal a change in their outlook on the company's prospects. As such, it provides no new material information to warrant a change in investment recommendation, and a 'hold' stance is appropriate for investors already positioned in NBIX.

Keywords

NBIX, Neurocrine Biosciences, Form 4, Insider Transaction, RSU Vesting, Stock Compensation, Jude Onyia, Chief Scientific Officer